<DOC>
	<DOCNO>NCT02533765</DOCNO>
	<brief_summary>This open-label , single-arm , two-stage phase II trial olaparib patient relapsed/refractory metastatic germ cell cancer . The primary objective evaluate preliminary activity Olaparib GCT tumor . The secondary objective evaluate safety Olaparib patient cisplatin-refractory GCT .</brief_summary>
	<brief_title>Olaparib Salvage Treatment Cisplatin-resistant Germ Cell Tumor</brief_title>
	<detailed_description>This proof-of principle open-label , single-arm , two-stage phase II trial olaparib 300 mg twice daily patient relapsed/refractory metastatic germ cell cancer . The study recruit 10 patient , response see study terminate . If one responses observe , 19 patient ( total 29 patient ) enrol . If 4 first 29 evaluable patient achieve objective response , study patient metastatic germ cell cancer warrant . The main inclusion criterion : - Patient metastatic gonadal GCT extragonadal GCT originate retroperitoneum mediastinum . - Disease progression cisplatin-based chemotherapy disease progression relapse high-dose chemotherapy disease progression relapse least 2 different cisplatin-based regimen - At least one measurable lesion accurately assess CT/MRI/plain x-ray ) baseline follow visit . The study analyze intent-to-treat basis . Secondary parameter analyze exploratively intent-to-treat population . Correlations biomarkers ( PAR , poly adenosine diphosphate-ribose polymerase ( PARP-1 ) , PTEN , XPA , ERCC1-3 , XPF , FanD2 , γ-H2AX ) expression paraffin-embedded tumor sample clinical outcome perform exploratory intent . Plasma sample collect baseline response/progression possible retrospective biomarkers study .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients ≥ 18 year old 2 . Histologically verified metastatic gonadal GCT extragonadal GCT originate retroperitoneum mediastinum . 3 . Disease progression cisplatinbased chemotherapy disease progression relapse highdose chemotherapy disease progression relapse least 2 different cisplatinbased regimen 4. patient progress cisplatinbased therapy eligible highdose chemotherapy 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) : 02 6 . Life expectancy ≥3 month 7 . At baseline adequate function liver , kidneys bone marrow Neutrophils ≥ 1500 /mm3 ; Hemoglobin ≥ 9.0 g/dL ; Platelets ≥ 80 x109/L ; Creatinine ≤ 1.5x upper limit normal ( ULN ) In case liver metastasis increase level follow three parameter acceptable : Bilirubin ≤ 1.5 x ULN serum glutamate oxaloacetate transaminase ( SGOT ( AST ) ≤2.5 x ULN serum glutamate pyruvate transaminase ( SGPT ( ALT ) &lt; 2.5 x ULN ; 8 . Signed informed consent expect cooperation patient treatment follow must obtain document accord International Conference Harmonization Good Clinical Practice ( ICH GCP ) , national/local regulations.Patient willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . 9 . At least one measurable lesion accurately assess CT/MRI/plain xray ) baseline follow visit . Exclusion criterion : 1 . Systemic antitumor treatment within 21 day study entry 2 . Simultaneous radiotherapy target lesion 3 . Patients rest ECG QTc &gt; 470 msec detect 2 time point within 24 hour period family history long QT syndrome . If ECG demonstrate QTc &gt; 470 msec , patient eligible repeat ECG demonstrate QTc ≤470 msec 4 . Patients experienced seizure seizure within 6 month study treatment currently treat cytochrome P450 enzyme induce antiepileptic drug seizure . 5 . Patients uncontrolled brain metastasis . 6 . Patients receive prohibited class inhibitor CYP3A4 ( see section 6.5.1 ) . 7 . Patients gastrointestinal disorder likely interfere absorption study medication . 8 . Patients acute toxicity due previous cancer treatment resolve Common Toxicity Criteria Adverse Effects ( NCICTCAE v 4.03 ) grade 0 1 exception chemotherapy induce alopecia grade 2 peripheral neuropathy . 9 . Patients affect myelodysplastic syndrome acute myeloid leukemia 10 . Known serologically positive HIV receive antiretroviral therapy 11 . Known seropositive active viral infection hepatitis B virus ( HBV ) ( patient HBsAg negative , antiHBs positive and/or hepatitis B core antigen ( AntiHBc ) positive , viral DNA negative eligible ) 12 . Known seropositive active infection hepatitis C virus ( HCV ) 13 . Patients unwilling unable comply protocol 14 . Patients unstable angina pectoris , myocardial infarction ≤ 6 month prior first study treatment , congestive heart failure New York Heart Association ( NYHA ) IIIIV serious uncontrolled cardiac arrhythmia 15 . Patients active uncontrolled infection 16 . Patients history another primary malignancy treatment ≤ 3 year , exception nonmelanoma skin cancer 17 . Patients undergone major surgery within 4 week prior start study drug ( e.g . intrathoracic , intraabdominal , intrapelvic ) significant traumatic injury , recover side effect within 6 week 18 . Patients participate another interventional clinical trial within 30 day study entry 19 . Other serious medical condition could impair ability patient participate study 20 . Active infection require systemic antibiotic , antiviral , antifungal medication 21 . Active cancer ( GCT ) include prior malignancy patient diseasefree ≤3 year ( except superficial basal cell skin cancer ) 22 . Patients know hypersensitivity combination/comparator agent 23 . Patients uncontrolled seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cisplatin-resistant</keyword>
	<keyword>Neoplasms , Germ Cell Embryonal</keyword>
	<keyword>Salvage treatment</keyword>
	<keyword>olaparib</keyword>
</DOC>